On October 12, 2023, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab). This approval specifically relates to the drug's efficacy, expanding its approved uses.
Background
Pembrolizumab, marketed as Keytruda, is an established therapeutic agent. This supplemental approval indicates an expansion of its previously approved indications based on new efficacy data.
What this means
The FDA's approval of a supplemental application for efficacy for Keytruda (pembrolizumab) signifies that new clinical data has demonstrated the drug's effectiveness for an expanded use. This could involve a new indication, a different patient population within an existing indication, or a new dosing regimen that has shown improved outcomes. For healthcare providers, this means pembrolizumab is now officially sanctioned for an additional therapeutic application, providing more options for patient care. Such approvals are critical for advancing treatment paradigms and ensuring that patients have access to therapies supported by robust scientific evidence.
Source
The information for this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 125514 S-138, was granted on October 12, 2023, and is publicly accessible on the accessdata.fda.gov website.